Background: Ceftazidime/avibactam is approved for complicated intra-abdominal and urinary tract infections (UTIs) based on results from randomized controlled trials (RCTs). Data regarding its effectiveness in treating hospital-acquired infections or resistant pathogens have not been systematically compiled.
Introduction
The prevalence of MDR Gram-negative bacteria, including ESBLproducing Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae (CRE) is increasing globally with a high risk of morbidity and mortality from these infections. 1 Carbapenems are considered by some to be the treatment of choice in serious infections caused by ESBL-producing bacteria; 2 however, carbapenem resistance is now emerging and carbapenem-sparing regimens are warranted. [3] [4] [5] Ceftazidime/avibactam has in vitro activity against Ambler class A, class C and some class D b-lactamase-producing bacteria, including Enterobacteriaceae and Pseudomonas aeruginosa. It has no activity against metallo-b-lactamase-producing organisms. [6] [7] [8] Based on several randomized control trials (RCTs), ceftazidime/avibactam was approved by the US FDA and EMA for the treatment of complicated urinary tract infection (cUTI) and complicated intra-abdominal infection (cIAI) in adults with limited or no alternative treatment options. 8 Small series have also demonstrated the effectiveness of this drug for the treatment of CRE infections. 9, 10 In an era of increasing resistance, a b-lactam drug with a broad spectrum may have the potential to be used as empirical therapy for various hospital-acquired infections in locations with high resistance rates. We aimed to evaluate whether the existing evidence supports ceftazidime/avibactam as empirical therapy in such conditions. We performed a systemic review and metaanalysis compiling all RCTs assessing the efficacy and safety of ceftazidime/avibactam for the treatment of various bacterial infections. We planned to assess the efficacy of this drug for the treatment of complicated infections and specifically for subgroups of patients infected with resistant pathogens. 
Methods
This systematic review and meta-analysis was conducted according to the PRISMA guidelines. 11 
Inclusion criteria and outcomes
We included RCTs that compared ceftazidime/avibactam, with or without metronidazole, versus any other antibiotic regimen for the treatment of any infection among adult patients.
The primary outcome was 30 day all-cause mortality and if that was unavailable, mortality at the end of follow-up. Secondary outcomes included: clinical response, as defined in individual studies; microbiological response (per patient and per pathogen, as available); superinfections; development of resistance; any adverse events (AEs) and serious AEs (SAEs), AEs requiring discontinuation, renal and liver AEs, and Clostridium difficile-associated diarrhoea.
Search strategy and selection criteria
We searched the PubMed, Cochrane Central Register of Controlled Trials (Central) and LILACS databases. The search term 'ceftazidime/avibactam' OR 'avibactam' OR 'NXL104' OR 'AVE1330A' was combined with the Cochrane filter for RCTs for the PubMed search. 12 For the Cochrane library and LILACS databases search, the term 'ceftazidime/avibactam' OR 'avibactam' OR 'NXL104' OR 'AVE1330A' was used. Unpublished trials were sought in references of all selected studies, relevant conference proceedings, trial registries and ongoing trial databases and through personal contact with the investigators of the included studies. No language or date restrictions were imposed. The last search was conducted in December 2017. For all outcomes we extracted data on the largest patient population available. Intention-to-treat data were mostly unavailable from the included trials, thus data were extracted by modified or microbiologically modified intention-to-treat population if available, and otherwise by clinically or microbiologically evaluated population, as defined in individual trials.
Study selection and data extraction
We planned to address antibiotic resistance data as suggested by Leibovici et al. 13 Risk of bias was assessed using the following domains recommended by the Cochrane handbook:
12 allocation sequence generation and allocation concealment, blinding, incomplete outcome data assessment, selective outcome reporting and early termination of the trial. These were graded as low, high or unknown risk of bias according to the criteria suggested by the Cochrane handbook. 12 In order to assess the effect of risk of bias on outcomes, we planned to perform sensitivity analyses by the above elaborated domains.
For all included studies we recorded the type of infection assessed, pathogens, race, gender, mean age, BMI, CL CR , mean APACHE II score and proportion of the study population with monomicrobial infection, bacteraemia, APACHE II score .10, prior antibiotic use/failure and a baseline resistant pathogen.
Statistical analysis
We compiled relative risks (RRs) and 95% CIs of individual trials using a Mantel-Haenszel fixed or random effects model. Heterogeneity in the results of the trials was assessed using the v 2 test for heterogeneity and the I 2 measure of inconsistency. 14 
Results
A flow chart of the trials is presented in Figure 1 . Seven publications representing eight trials (4093 patients) that compared ceftazidime/avibactam + metronidazole versus any other antibiotic regimen for treatment of cUTI, cIAI and nosocomial pneumonia were included in this review. [15] [16] [17] [18] [19] [20] [21] The main comparator was a carbapenem ( Table 1) . Place of infection acquisition was explicitly described as hospital-acquired in only one trial. 19 All included trials were industry-sponsored multicentre trials. All but three publications 15, 16, 20 were designed as non-inferiority trials using a non-inferiority margin of 10%-12.5%. All trials had low risk of bias for allocation generation, allocation concealment, selective outcome reporting and incomplete outcome assessment. One publication 15 was open-label whereas all others were double-blinded. This publication also reported on early discontinuation of recruitment because the funder considered that a sufficient number of patients had been recruited by that time.
Dosing and route of administration of study drugs are presented in Table S1 (available as Supplementary data at JAC Online). Planned duration of therapy ranged between 5 and 21 days. Additional antibiotics permitted are shown in Table 1 . Follow-up in all trials was performed at end-of-treatment (EOT), test-of-cure (TOC) and late-follow-up (LFU) visits (see Table S2 for definitions in individual trials).
Primary outcome: 30 day all-cause mortality (Figure 2)
Overall, 36/610 (5.9%) patients died within 30 days in the ceftazidime/avibactam arm and 34/629 (5.4%) in the comparator arm. Mortality for long-term follow-up was 64/1956 (3.3%) in the ceftazidime/avibactam arm and 52/1957 (2.7%) in the comparator arm.
All-cause 30 day mortality was reported in four trials including 1239 patients (one UTI, 15 two IAI 15, 16 and one pneumonia trial 19 ). No significant difference in mortality was demonstrated between ceftazidime/avibactam and the comparator (RR 1.1, 95% CI 0.7-1.72, P " 0.69, I
2 " 0). Seven trials including 3915 patients reported all-cause mortality at LFU with no significant difference between study arms (RR 1.23, 95% CI 0.87-1.76, P " 0.25, I
2 " 0). Among subcategories of type of infection, no statistically significant difference in mortality was demonstrated ( Figure 2 ).
Data on mortality in the pre-specified subgroups were not available in any of the trials. Sensitivity analysis separating trials by blinding demonstrated no significant difference in mortality at LFU between study arms among studies that were double-blinded (RR 1.27, 95% CI 0.88-1.84, 5 trials, P " 0.20, I
2 " 0%).
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Clinical response
Clinical response in the included trials was evaluated at EOT, TOC and LFU (definitions of timepoints of evaluation are summarized in Table S2 ). At all of these timepoints no significant difference was demonstrated between study arms. Eight trials reported clinical response at the TOC visit (3292 patients) with no difference between study arms (RR 0.98, 95% CI 0.96-1.01, P " 0.21, I 2 " 0) ( Table 2) .
Microbiological response (Figure 3)
We evaluated microbiological response at both patient level and isolate level. Most of the results for microbiological response stemmed from cUTI trials, as expected considering the complexity of repeating cultures in cIAIs.
Microbiological response per patient at the EOT was reported in four trials (1506 patients, 1151 of them cUTI) with no significant difference between study arms (RR 0.99, 95% CI 0.96-1.02, 2 " 0). Similar results were reported at the TOC visit (5 trials, 1652 patients, RR 1.04, 95% CI 0.93-1.17, P " 0.51, I
2 " 73%), (Figure 3 ). Compiling only trials including patients with UTI, a significantly higher rate of microbiological response was demonstrated among the ceftazidime/avibactam arm (three trials, 1153 patients, RR 1.14, 95% CI 1.0-1.29, P " 0.05, I
2 " 51%). The significant heterogeneity was eliminated by excluding the study of Carmeli et al. 15 without changing the results. At LFU, three UTI trials (1147 patients) also demonstrated a statistically significant advantage of ceftazidime/avibactam in terms of microbiological response (RR 1.15, 95% CI 1.05-1.26, P " 0.002, I
2 " 12%). Microbiological response per isolate at TOC was reported from four trials (1419 patients) with significantly higher microbiological response in the ceftazidime/avibactam arm, stemming from two Systematic review JAC UTI trials (RR 1.14, 95% CI 1.04-1.24, P " 0.004, I 2 " 68% for UTI trials).
Subgroup analyses
For patients with bacteraemia, four trials evaluating 152 patients demonstrated no significant difference in clinical response among study arms (RR 1.00, 95% CI 0.82-1.13, P " 0.97, I
2 " 0%). No statistically significant difference in clinical response was demonstrated among patients with APACHE II score .10 (RR 0.93, 95% CI 0.86-1.01, P " 0.07, five trials, 995 patients, I
2 " 0%). Eight trials (241 patients) reported on clinical response among patients with Pseudomonas aeruginosa infection without significant differences between study arms (RR 0.93, 95% CI 0.83-1.05, P " 0.24, I
2 " 0%). Clinical response among patients with ceftazidime-resistant pathogens was also without significant difference between study arms (RR 1.02, 95% CI 0.94-1.10, P " 0.66, I
2 " 0%, 6 trials, 480 patients). Several duplicate publications characterized b-lactamases in isolates from included patients [22] [23] [24] [25] [26] (not described for the trial by Qin et al.
18
). Resistance profiles of isolates were determined according to the CLSI guidelines using the screening and confirmatory tests. 27 Enterobacteriaceae displaying ceftriaxone and/or ceftazidime MIC 2 mg/L were further tested for narrow and extended b-lactamases genes. Among a total of 2327 Enterobacteriaceae isolated from all included trials, 613 (26%) were characterized as ESBL positive with variability across trials (highest rates of .60% in two trials). 15, 19 Clinical response at TOC was reported among patients with a positive screen in three trials (196 patients) with a response rate of 86% and without significant difference between study arms (RR 1.02, 95% CI 0.91-1.14, P " 0.76, without heterogeneity). 16, 17, 20 The number of carbapenemase-producing Enterobacteriaceae (CPE) was highest in two trials: Carmeli et al. 15 (including patients with ceftazidimeresistant bacteria) reported carbapenemases in 13/314 isolates (4%); and Torres et al. 19 (including patients with nosocomial pneumonia) with 11/171 (6%). In the study of Carmeli et al., 15 13/27 Pseudomonas isolates were reported as harbouring class B or D b-lactamases. Other studies reported between zero and five carbapenemase-producing isolates. Response rates of patients with ESBL-, AmpC-or carbapenemase-producing organisms were reported from only one trial and thus were not compiled.
Adverse events (Figure 4)
Any AEs were reported in eight trials including 3988 patients. These included 974/1993 (49%) AEs in the ceftazidime/avibactam group and 943/1995 (47%) in the comparator group (RR 1.03, 95% CI 0.97-1.10, P " 0.28, I
2 " 14%). AEs requiring discontinuation were without significant difference between arms (RR 1.55, 95% CI 0.98-2.46, P " 0.06, I
2 " 0%). Among two trials evaluating cIAI Systematic review a significantly higher rate of discontinuation was demonstrated for the ceftazidime/avibactam group (RR 2.11, 95% CI 1.00-4.44, P " 0.05, I 2 " 0%). SAEs were statistically significantly more common in the ceftazidime/avibactam arm (RR 1.24, 95% CI 1.00-1.54, P " 0.05, I
2 " 0%) (Figure 4 ). More detailed data concerning the nature of these SAEs were not available. Gastrointestinal AEs were significantly more common in the ceftazidime/avibactam group in trials evaluating cIAI (RR 1.61, 95% CI 1.31-1.97, P , 0.01, I 2 " 31%). C. difficile-associated diarrhoea was reported in three trials with rates of 3/1255 patients in the ceftazidime/avibactam group and 1/1255 patients in the comparator group. Creatinine increase was significantly more common in the ceftazidime/avibactam group (RR 3.00, 95% CI 1.09-8.20, P " 0.03, I
2 " 0%), though this result stemmed from one study. 17 Other AEs had no significant difference between study arms, including liver function abnormalities, pyrexia, peripheral oedema, hypersensitivity reactions and neurological AEs.
Development of resistance
Resistance to study drugs at baseline is summarized in Table S3 . Two trials reported at least a 4-fold increase in MIC at TOC: Torres et al. 19 reported such an increase in 2/125 (1.6%) pathogens in the ceftazidime/avibactam group and 11/131 (8.4%) in the comparator group; and Wagenlehner et al. 21 reported 8/393 (2.0%) and 3/317 (0.9%), respectively.
Other outcomes
Superinfections were documented in three studies: two studies described surgical site infections in a total of 16/630 (2.5%) patients in the ceftazidime/avibactam arm and 17/631 (2.7%) patients in the comparator arm. 16, 17 Another study reported 0/125 and 3/131 superinfections among ceftazidime/avibactam and comparator, respectively, in patients with nosocomial pneumonia. 19 Duration of hospitalization and number of readmissions were not reported in any of the trials.
Discussion
We conducted a systematic review and meta-analysis of RCTs comparing ceftazidime/avibactam with any other comparator, mainly carbapenems. We found no significant difference in 30 day mortality and mortality at the end of follow-up between study arms. Clinical response rates were also similar between ceftazidime/avibactam and comparators. Microbiological response was significantly higher for the ceftazidime/avibactam arm in cUTI trials. In trials assessing patients with cIAIs, gastrointestinal AEs and AEs requiring drug discontinuation were significantly more common in the ceftazidime/avibactam arm. SAEs were significantly more common with ceftazidime/avibactam.
No significant difference in clinical response was documented for patients with bacteraemia or patients with ceftazidimeresistant pathogens. Data were not available for the pre-planned subgroups of patients with hospital-acquired infections and CRE infections. However, approximately a quarter of baseline isolates in the included trials possessed ESBLs, making the meta-analysis results valid in the setting of hospital-acquired infections in a centre with similar rates of ESBL infections.
The comparator in the vast majority of cases was a carbapenem. Use of carbapenems is described to be associated with development of CRE and thus, carbapenems are usually used as last-resort drugs. 28, 29 Owing to the limited data regarding resistance development in our review we cannot draw conclusions on the association between any of the studied drugs and CRE development. In addition, in a previous systematic review and metaanalysis, higher rates of C. difficile-associated diarrhoea were reported with carbapenems compared with b-lactam/b-lactamase inhibitor combinations. 30 This could also not be supported by the current review owing to limited reporting on C. difficile in the included trials.
The data presented in this review are from recent RCTs with high methodological quality conducted in various geographical locations. However, there are several limitations for this review. Mortality in the included trials was 6% at 30 days. This rate is lower than that described for similar infections in non-randomized studies, for example 12.1% 30 day mortality for complicated diverticulitis, 31 10.1% for cIAI in general 32 and above 20% for nosocomial pneumonia. 33 Lower mortality in RCTs involving antibiotics compared with non-randomized studies has been previously discussed by Paul et al., 34 raising concerns regarding the limited external validity of RCTs in infectious diseases. Exclusion criteria in the trials included in our review were severe renal or liver impairment, immunocompromised and no expected response to antibiotics within 5-21 days. It is possible that excluding patients fulfilling these criteria had an influence on the lower mortality rate compared with non-randomized studies. In addition, conclusions on the drug effectiveness and safety in such patients cannot be drawn. The higher microbiological response rate demonstrated for ceftazidime/avibactam in cUTI studies, stemming mainly from the study by Carmeli et al., 15 might be because of a better response of carbapenemase-producing pathogens included in this study to ceftazidime/avibactam. Most trials used the maximum approved dose of ceftazidime/avibactam in an extended infusion, as opposed to the comparator used in most trials, which was at a low dose and with non-extended administration. We assume that dosage and route of administration have no significant influence in cUTI studies; however, it may bias the results in favour of ceftazidime/avibactam in other infections, as suggested by Kalil and Klompas 35 reviewing the RCT by Torres et al. 19 including nosocomial pneumonia patients. In conclusion, ceftazidime/avibactam is clinically as effective as carbapenems for the treatment of cUTI, cIAI and nosocomial pneumonia in a setting in which 25% of Enterobacteriaceae are ESBL positive. Microbiological response in patients with cUTI is superior with ceftazidime/avibactam. Safety of the drug should be further evaluated due to the higher rate of SAEs compared with carbapenems. Data are too scarce to draw conclusions regarding effectiveness of the drug in CRE infections. Ceftazidime/avibactam may probably be used as a carbapenem-sparing drug, though studies evaluating the drug's effectiveness specifically for ESBL infections are needed. In addition, individual patient data metaanalysis compiling ESBL infections from the included trials may also be helpful.
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